Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Costello

Clinical Cardiac Electrophysiology Philadelphia, PA Doctor of Osteopathy

NPI 1699037291 CMS profile 1236863

4190 City Ave, Pcom, Philadelphia, PA 19131

Open in the dashboard

General payments

$32,587

404 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$69,258 paid to institutions, not to them · program years 2024–2025

Through program year 2025, John Costello of Philadelphia, PA is reported in the CMS Open Payments database as having received $32,587 across 404 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $69,258 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 64th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,639 80
2024 General $1,646 72
2023 General $2,531 68
2022 General $2,897 81
2021 General $2,605 50
2020 General $856 21
2019 General $15,413 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Costello
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to John Costello were reported at $6,639. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year John Costello Clinical Cardiac Electrophysiology median Middle half National median
2019 $15,413 $2,361 $585–$8,260 $163
2020 $856 $993 $247–$4,351 $114
2021 $2,605 $1,185 $326–$4,739 $132
2022 $2,897 $2,073 $554–$6,789 $149
2023 $2,531 $2,568 $759–$8,159 $160
2024 $1,646 $2,557 $703–$7,403 $164
2025 $6,639 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $12,735 5 payments
  2. Boston Scientific Corporation $7,552 75 payments
  3. Abbott Laboratories $3,676 72 payments
  4. Biosense Webster, Inc. $1,631 36 payments
  5. Impulse Dynamics (USA) Inc. $1,411 47 payments
  6. Biotronik Inc. $1,183 25 payments
  7. Philips Electronics North America Corporation $869 9 payments
  8. Atricure, Inc. $859 24 payments
  9. Respicardia, Inc. $352 1 payment
  10. Aziyo Biologics, Inc. $345 6 payments
  11. Other $1,974 104 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $12,500 1 payment
  2. Food and Beverage $11,775 379 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,050 2 payments
  4. Travel and Lodging $1,927 11 payments
  5. Consulting Fee $921 2 payments
  6. Education $414 9 payments
Products named General payments · program years 2019–2025
  1. FARAPULSE $5,000 1 payment
  2. Ensite Cardiac Mapping System $1,683 15 payments
  3. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $859 24 payments
  4. (9124) LM Undivided $830 7 payments
  5. General - Therapies $700 1 payment
  6. OPTIMIZER Cardiovascular Device $622 19 payments
  7. OPTIMIZER Cardiovascular Device $622 19 payments
  8. Carto 3 $614 20 payments
  9. WATCHMAN Access System $603 9 payments
  10. Optimizer Smart System $525 16 payments
  11. Other $10,363 330 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

629

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$298,246

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

43.2%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 158 $201,842
Xarelto Rivaroxaban Brand 40 $55,274
Entresto Sacubitril/Valsartan Brand 24 $26,025
Farxiga Dapagliflozin Propanediol Brand 16 $9,430
Metoprolol Succinate Generic 88 $1,671
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 20 $668
Atorvastatin Calcium Generic 35 $632
Metoprolol Tartrate Generic 79 $575
Rosuvastatin Calcium Generic 28 $536
Digoxin Generic 22 $489

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$477,747

Medicare's payments for the services billed

Medicare patients

2,153

Average age 75

Services billed

6,896

1,030 women, 1,123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 59%
Ischemic heart disease 56%
Arthritis 54%
Heart failure 47%
Diabetes 46%
Chronic kidney disease 41%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $43
$43 158 —
XARELTO
  • Janssen Pharmaceuticals, Inc $33
$33 40 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $30
$30 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $27
$27 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

404 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record